FREMONT, Calif., Feb. 25, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research titled Global Cell and Gene Therapy Market highlights that the market is projected to reach $25.00 billion by the end of 2027. The study also highlights that the market is set to witness a CAGR of 33.82% during 2021-2027. The growth is attributed to increasing incidences of cancer and other chronic diseases, and the increasing number of clinical trials, among others.
Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry. However, the technology for manufacturing these therapies is still at a nascent stage. The cell and gene therapy market further continues to add new players within the industry. With over 1000 clinical trials performed, the field is becoming more promising with time.
Market numbers on micro-segments that are influencing the market
More than 100 pipeline products present in the market
Market share analysis of more than 15 companies
Detailed global and regional market share analysis including the scrutiny of more than 15 countries
Who Should Buy This Report?
Manufacturers of cell and gene therapies
Pharmaceutical companies investing in the cell and gene therapy market
Research firms involved in clinical trials for cell and gene therapies
Cell and gene therapies companies interested in business expansion through partnerships or other synergistic activities
Besides these parameters, the study also encompasses market restraining factors, competition mapping, segmental analysis, and brief analysis of available drugs and FDA-approved cell and gene therapies in each therapeutic class in the last few years.
BIS Research study indicates that the increasing number of cell and gene therapies are in demand with driving factors such as increasing funding and investment in cell and gene therapies, and favorable regulatory environment and FDA approvals for cell and gene therapy products propelling the growth of the market.
The study also highlights the various emerging opportunities for the market, such as the rising number of drug approvals, a strong pipeline of cell and gene therapies, and an increasing number of mergers and acquisitions between companies operating in the cell and gene therapy market. The market intelligence report by BIS Research additionally throws a spotlight on the key industry restrains that are expected to have an influence in hampering the growth of the industry in the future.
In order to gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include product analysis, types of therapeutic class, pipeline analysis, region, and country. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. The product analysis of the global market includes data analysis on the cell and gene therapies approved along with the therapeutic class analysis.
Gene and cell therapy is the use of genes and cells for the treatment of genetic diseases. Genetic diseases are caused by errors, or mutations, in genes that lead to a loss or modification of protein molecules. These mutations can be passed down from parents to children or can happen spontaneously. The advanced therapy medicinal products (ATMPs), brought in use to tackle these diseases, comprise ground-breaking cell and gene therapies (CGT) and tissue engineered (TE) products, which are the result of decades of research and development in the field of medicine.
Emphasizing the dominance of North America among all the regions in the market in 2020 and 2027, Nitish Kumar Singh, Principal Analyst – BIS Research, states, "The therapy Zolgensma accounted for the largest share among all the cell and gene therapies, holding 13.96% of the global cell and gene therapy market in 2020. This segment is anticipated to grow at a significant CAGR during the forecast period 2021-2027. However, it is expected that the therapy Kymriah would witness the highest CAGR during the forecast period, 2021-2027."
Key insights have been drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., Renova Therapeutics, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.
The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.
How can market intelligence on the cell and gene therapy market add value to an organization's decision-making process?
Aid in product development
Help in targeting a segment for launching new therapies
Offer go-to-market strategies for the different source type
Help in analyzing technological substitutes and compares the specification
Aid in understanding the strategies opted by the key players
Assist in exploring the newer therapies
Aid in understanding the pipeline for cell and gene therapies
Insightful Questions Covered to Enable Companies to take Strategic Decisions
What are the different types of approved cell and gene therapies available in the respective markets?
What are the key development strategies implemented by the key players to stand out in this market?
What are the various manufacturing considerations within the cell and gene therapy market?
How do the key players' strategic collaborations provide a push to product development within the global cell and gene therapy market?
What are the regulations pertaining to the global cell and gene therapy market in different regions?
What are the initiatives implemented by different government bodies regulating the development and commercialization of cell and gene therapy products and associated platforms?
How has COVID-19 impacted the cell and gene therapy market?
How will the urgency of the pandemic influence the global cell and gene therapy market?
What are the leading companies dominating the global cell and gene therapy market?
What is the reimbursement scenario of the products offered in the global cell and gene therapy market?
Based on the product type, which therapy in the global cell and gene therapy market is anticipated to witness a massive rise in demand in the forecast period?
How is each segment of the global cell and gene therapy market expected to grow during the forecast period? What is the revenue expected to be generated by each segment by the end of 2027?
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.
Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate as well as custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.
BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past five years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.